Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +51.97%
#2 PondCoin PondCoin +49.80%
#3 Pons Pons +44.46%
#4 TENDIES TENDIES +38.89%
#5 StonkBroker StonkBroker +34.93%
#6 Purr Purr +30.18%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +29.85%
#8 Ocean Protocol Ocean Protocol +29.26%
#9 Magma Finance Magma Finance +29.13%
#10 SkyAI SkyAI +26.83%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Provectus Biopharmaceuticals, Inc. Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals, Inc.

PVCT
Rang in Aktien #28895
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology firm... Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology firm dedicated to pioneering immunotherapy treatments. These therapies are grounded in its proprietary halogenated xanthene platform. Among its key developments is PV-10, an experimental autolytic cancer immunotherapy. This treatment is being explored for a range of adult solid tumor malignancies, encompassing melanoma and various gastrointestinal cancers (such as hepatocellular carcinoma, metastatic colorectal cancer to the liver, metastatic neuroendocrine tumors to the liver, and metastatic uveal melanoma to the liver). It also targets pediatric solid tumors, including neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. Additionally, Provectus is advancing oral formulations of pharmaceutical-grade rose bengal sodium (cGMP RBS) to combat a broad spectrum of conditions. These include adult solid tumors (such as head and neck, breast, testicular, and colorectal cancers), pediatric blood cancers like leukemia, acute respiratory syndromes such as coronavirus, infections caused by multi-drug resistant bacteria (specifically Gram-negative bacteria), and certain ocular conditions, notably infectious keratitis. Furthermore, the company is progressing PH-10, an investigational immuno-dermatology agent designed to address inflammatory skin conditions like psoriasis and atopic dermatitis. Originally established in 2002, the company was initially named Provectus Pharmaceuticals, Inc., before rebranding as Provectus Biopharmaceuticals, Inc. in December 2013. Its operations are headquartered in Knoxville, Tennessee.
Aktienkurs
$0.0573
Marktkapitalisierung
$24.08M
Veränderung (1 Tag)
0.53%
Veränderung (1 Jahr)
-28.55%
Land
US
Handel Provectus Biopharmaceuticals, Inc. (PVCT)

Kategorie

Healthcare
Kursverlauf für Provectus Biopharmaceuticals, Inc. (PVCT)
Höchster Schlusskurs: $0.06 am 2026-08-01

Niedrigster Schlusskurs: $1.50K am 1997-01-01
Kursverlauf der Aktie von Provectus Biopharmaceuticals, Inc. von 1997 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) 4.90%
2025 -49.43%
2024 14.98%
2023 -8.24%
2022 129.37%
2021 -13.91%
2020 -4.11%
2019 6.20%
2018 9.56%
2017 254.83%
2016 -96.41%
2015 -50.33%
2014 -42.52%
2013 161.88%
2012 -24.41%
2011 -19.14%
2010 2.53%
2009 -1.05%
2008 -53.93%
2007 68.37%
2006 27.17%
2005 62.37%
2004 -51.83%
2003 269.90%
2002 -99.95%
2001 3.10%
2000 -61.25%
1999 0.00%
1998 0.00%
1997 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $552.07 41.28%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $168.77 504.69%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.03K 57.19%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $117.42 -19.34%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $753.28 8.59%
CH